Patent: 10,329,314
✉ Email this page to a colleague
Summary for Patent: 10,329,314
| Title: | Soluble C5aR antagonists |
| Abstract: | Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): ##STR00001## including stereoisomers and pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2 and R.sup.3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. |
| Inventor(s): | Fan; Pingchen (Fremont, CA), Krasinski; Antoni (Sunnyvale, CA), Mali; Venkat Reddy (Cupertino, CA), Miao; Shichang (Foster City, CA), Punna; Sreenivas (Sunnyvale, CA), Song; Yang (Foster City, CA), Stella; Valentino J. (Lawrence, KS), Zeng; Yibin (Foster City, CA), Zhang; Penglie (Foster City, CA) |
| Assignee: | ChemoCentryx, Inc. (Mountain View, CA) |
| Application Number: | 15/908,508 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,329,314
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Clinigen, Inc. | PROLEUKIN | aldesleukin | For Injection | 103293 | 05/05/1992 | ⤷ Try a Trial | 2036-04-04 |
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2036-04-04 |
| Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 05/12/1998 | ⤷ Try a Trial | 2036-04-04 |
| Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 01/02/2003 | ⤷ Try a Trial | 2036-04-04 |
| Eisai, Incorporated | ONTAK | denileukin diftitox | Injection | 103767 | 02/05/1999 | ⤷ Try a Trial | 2036-04-04 |
| Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2036-04-04 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
